Arizona State Retirement System Acquires 6,296 Shares of Merck & Co., Inc. $MRK

Arizona State Retirement System lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 0.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 686,042 shares of the company’s stock after buying an additional 6,296 shares during the quarter. Arizona State Retirement System’s holdings in Merck & Co., Inc. were worth $88,156,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. California State Teachers Retirement System raised its stake in shares of Merck & Co., Inc. by 12,537.4% during the 2nd quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company’s stock valued at $62,286,552,000 after purchasing an additional 480,884,635 shares during the period. Norges Bank bought a new position in Merck & Co., Inc. in the 4th quarter worth about $3,997,933,000. Wellington Management Group LLP boosted its stake in Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the period. Cardano Risk Management B.V. purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $1,012,530,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Merck & Co., Inc. by 37.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after buying an additional 5,152,069 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Guggenheim raised its price target for Merck (MRK) to $170 from $146 and upgraded the shares to “buy,” implying roughly 14.5% potential upside from the referenced price. The upgrade provides a near-term positive catalyst and signals increased confidence in Merck’s growth prospects.
• Positive Sentiment: Analysts continue to point to Keytruda as the company’s primary growth engine, while Merck’s pipeline and newer products could help offset the expected impact of the 2028 patent cliff. This supports the stock’s strong performance and may reinforce the bullish outlook. Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
• Positive Sentiment: Merck will participate in Morgan Stanley’s 24th Annual Global Healthcare Conference. Management commentary on Keytruda demand, the pipeline, and preparations for the patent expiration could provide an additional catalyst if it exceeds investor expectations. Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
• Neutral Sentiment: Reports forecast continued expansion in the global vaccine and pulmonary arterial hypertension markets, areas in which Merck participates. However, the market reports do not announce a new Merck contract, product approval, or financial forecast, limiting their immediate stock impact.
• Neutral Sentiment: Merck’s pilot with The Hashgraph Group and PwC Germany involves blockchain-based cocoa traceability. The initiative may support corporate technology and sustainability goals but is unlikely to materially affect near-term earnings. The Hashgraph Group and Merck Develop Cocoa Traceability Solution
• Negative Sentiment: With MRK near a record level and trading at a high earnings multiple, investors may require continued execution to justify the valuation. The eventual loss of Keytruda exclusivity remains the key long-term risk, while the earlier Gardasil sales downturn shows that vaccine weakness can pressure results.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock traded down $1.89 during mid-day trading on Tuesday, hitting $148.44. 11,184,680 shares of the company traded hands, compared to its average volume of 10,784,977. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $156.92. The stock has a market cap of $366.23 billion, a price-to-earnings ratio of 118.75, a price-to-earnings-growth ratio of 6.54 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a fifty day moving average price of $135.06 and a 200-day moving average price of $123.73.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the prior year, the firm earned $2.13 EPS. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. Royal Bank Of Canada cut shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and increased their target price for the stock from $142.00 to $150.00 in a research note on Thursday, August 20th. The Goldman Sachs Group raised their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a report on Friday, August 21st. Finally, Wells Fargo & Company boosted their price target on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday. Fifteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus target price of $149.80.

Insider Transactions at Merck & Co., Inc.

In related news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard R. Deluca sold 20,784 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the transaction, the executive vice president directly owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. This trade represents a 13.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.